BiotechTube
Home/ReST Therapeutics/Gilles Rubinstenn, PhD, MBA
GR

Gilles Rubinstenn, PhD, MBA

Chief Innovation Officer, Chairman & Founder

ReST Therapeutics

Therapeutic Areas

NeuropsychiatryPost-Traumatic Stress Disorder (PTSD)Alzheimer's Disease

ReST Therapeutics Pipeline

DrugIndicationPhase
RST-101Post-Traumatic Stress Disorder (PTSD) - Early TreatmentPreclinical
FENMAlzheimer's Disease / Post-Traumatic Stress DisorderPhase 1

Leadership Team at ReST Therapeutics

AR
Anthony R. Franco, JD
General Manager
RB
Reina Benabou, MD, PhD
Chief Medical Officer
View full ReST Therapeutics profile